PacBio's Q3 Revenues Jump 164 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday that its third quarter 2013 revenues climbed 164 percent year over year and grew 23 percent sequentially.

The Menlo Park, Calif.-based single-molecule sequencing technologies firm reported Q3 revenues of $7.4 million, compared to just $2.8 million in Q3 2012 and up from $6 million in Q2 2013. It beat the consensus Wall Street estimate of $7.1 million in revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.